Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.50 |
| ▸ | MAP3K12 | Q12852 | 14/20 | 0.47 |
| ▸ | ADK | P55263 | 1/20 | 0.44 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.42 |
| ▸ | DLK1 | P80370 | 1/20 | 0.42 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22409840 | 1.00 | LRRK2 (0.50) | LRRK2MAP3K12ADKMAP3K13DLK1 | |
| SCHEMBL22425335 | 0.83 | LRRK2 (0.53) | LRRK2MAP3K12MAP3K13DLK1ATR | |
| SCHEMBL22425585 | 0.80 | LRRK2 (0.47) | LRRK2MAP3K12MAP3K13DLK1ATR | |
| SCHEMBL24454015 | 0.80 | LRRK2 (0.47) | LRRK2MAP3K12MAP3K13DLK1ATR | |
| SCHEMBL22425587 | 0.80 | LRRK2 (0.47) | LRRK2MAP3K12MAP3K13DLK1ATR | |
| SCHEMBL21588292 | 0.78 | ADK (0.49) | MAP3K12ADKMAP3K13DLK1PDE10A | |
| SCHEMBL21588369 | 0.78 | ADK (0.49) | MAP3K12ADKMAP3K13DLK1PDE10A | |
| SCHEMBL22425261 | 0.74 | USP30 (0.36) | — | |
| SCHEMBL30749108 | 0.73 | MAP3K12 (0.48) | MAP3K12MAP3K13DLK1 | |
| SCHEMBL30605628 | 0.72 | MAP3K12 (0.45) | LRRK2MAP3K12ADKMAP3K13DLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2022-05-26 | — | — | US | disclosed |
| WO-2020182666-A1 | SMALL MOLECULE MODULATORS OF IL-17 | LEO PHARMA A/S (DK) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162191-A1 | SMALL MOLECULE MODULATORS OF IL-17 | IL17A, IL15, IL2 | LRRK2 3566/4885MAP3K12 1333/4885ADK 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.